JP2021519289A5 - - Google Patents
Info
- Publication number
- JP2021519289A5 JP2021519289A5 JP2020551503A JP2020551503A JP2021519289A5 JP 2021519289 A5 JP2021519289 A5 JP 2021519289A5 JP 2020551503 A JP2020551503 A JP 2020551503A JP 2020551503 A JP2020551503 A JP 2020551503A JP 2021519289 A5 JP2021519289 A5 JP 2021519289A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cells
- cancer
- cytotoxic
- therapeutic
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023216572A JP2024045111A (ja) | 2018-03-27 | 2023-12-22 | ガイダンス及びナビゲーションコントロール蛋白質の生産及び使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862648888P | 2018-03-27 | 2018-03-27 | |
| US201862648880P | 2018-03-27 | 2018-03-27 | |
| US62/648,888 | 2018-03-27 | ||
| US62/648,880 | 2018-03-27 | ||
| PCT/US2019/024111 WO2019191125A1 (en) | 2018-03-27 | 2019-03-26 | Methods of making and using guidance and navigation control proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023216572A Division JP2024045111A (ja) | 2018-03-27 | 2023-12-22 | ガイダンス及びナビゲーションコントロール蛋白質の生産及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021519289A JP2021519289A (ja) | 2021-08-10 |
| JP2021519289A5 true JP2021519289A5 (https=) | 2022-05-11 |
| JPWO2019191125A5 JPWO2019191125A5 (https=) | 2022-05-11 |
Family
ID=68060498
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551503A Pending JP2021519289A (ja) | 2018-03-27 | 2019-03-26 | ガイダンス及びナビゲーションコントロール蛋白質の生産及び使用方法 |
| JP2020551549A Active JP7573441B2 (ja) | 2018-03-27 | 2019-03-26 | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 |
| JP2023216572A Pending JP2024045111A (ja) | 2018-03-27 | 2023-12-22 | ガイダンス及びナビゲーションコントロール蛋白質の生産及び使用方法 |
| JP2024180215A Active JP7781243B2 (ja) | 2018-03-27 | 2024-10-15 | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551549A Active JP7573441B2 (ja) | 2018-03-27 | 2019-03-26 | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 |
| JP2023216572A Pending JP2024045111A (ja) | 2018-03-27 | 2023-12-22 | ガイダンス及びナビゲーションコントロール蛋白質の生産及び使用方法 |
| JP2024180215A Active JP7781243B2 (ja) | 2018-03-27 | 2024-10-15 | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20210008113A1 (https=) |
| EP (2) | EP3774918A4 (https=) |
| JP (4) | JP2021519289A (https=) |
| KR (2) | KR20200139130A (https=) |
| CN (5) | CN111527108A (https=) |
| AU (4) | AU2019243453B2 (https=) |
| CA (2) | CA3094997A1 (https=) |
| IL (4) | IL271348B2 (https=) |
| SG (2) | SG11202008470WA (https=) |
| TW (2) | TW202003037A (https=) |
| WO (2) | WO2019191125A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250376531A9 (en) * | 2017-06-25 | 2025-12-11 | Systimmune, Inc. | Anti-4-1bb antibodies and methods of making and using thereof |
| EP3645738A4 (en) * | 2017-06-25 | 2021-08-18 | Systimmune, Inc. | ANTI-PD-L1 ANTIBODIES AND METHOD FOR MANUFACTURING AND USING THEREOF |
| CN116948035A (zh) * | 2017-06-25 | 2023-10-27 | 西雅图免疫公司 | 多特异性抗体及其制备和使用方法 |
| TWI828625B (zh) * | 2017-06-25 | 2024-01-11 | 美商西雅圖免疫公司 | 引導及導航控制蛋白質以及彼之製造及使用方法 |
| WO2019005636A2 (en) * | 2017-06-25 | 2019-01-03 | Systimmune, Inc. | ANTI-ROR1 ANTIBODIES AND METHODS OF PREPARATION AND USE |
| SG11201912865VA (en) * | 2017-06-25 | 2020-01-30 | Systimmune Inc | Multi-specific antibodies and methods of making and using thereof |
| US20210008113A1 (en) * | 2018-03-27 | 2021-01-14 | Systimmune, Inc. | Methods of making and using guidance and navigation control proteins |
| CN114502203B (zh) * | 2019-11-06 | 2024-07-19 | 成都百利多特生物药业有限责任公司 | 制导和导航控制蛋白及其制备和使用方法 |
| EP4077374A4 (en) * | 2019-12-20 | 2023-12-27 | Kisoji Biotechnology Inc. | POLYPEPTIDES, PROTEIN COMPLEXES AND METHODS FOR PRODUCING THE SAME |
| WO2021178253A1 (en) * | 2020-03-03 | 2021-09-10 | Systimmune, Inc. | Anti-cd19 antibodies and methods of using and making thereof |
| TWI874613B (zh) * | 2020-03-17 | 2025-03-01 | 美商西雅圖免疫公司 | 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法 |
| FI4284512T3 (fi) | 2021-01-28 | 2025-05-22 | Regeneron Pharma | Koostumuksia ja menetelmiä sytokiinien vapautumisoireyhtymän hoitamiseksi |
| AU2022283436A1 (en) * | 2021-05-28 | 2023-11-30 | Dana-Farber Cancer Institute, Inc. | Multi-specific antibody constructs against the muc1-c/extracellular domain ( muc1-c/ecd) |
| TW202334223A (zh) | 2021-11-11 | 2023-09-01 | 美商再生元醫藥公司 | Ｃｄ２０－ｐｄ１結合分子及其使用方法 |
| CN119546329A (zh) | 2022-04-11 | 2025-02-28 | 瑞泽恩制药公司 | 用于通用肿瘤细胞杀伤的组合物和方法 |
| JP2025512953A (ja) * | 2022-04-11 | 2025-04-22 | アストラゼネカ・アクチエボラーグ | Ｔ細胞結合タンパク質 |
| KR20250151441A (ko) | 2023-02-17 | 2025-10-21 | 리제너론 파마슈티칼스 인코포레이티드 | Cd3/taa 이중특이적 항체에 대해 반응성인 유도된 nk 세포 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1354600A1 (en) * | 2002-04-19 | 2003-10-22 | Affimed Therapeutics AG | Antibody combination useful for tumor therapy |
| JP6190723B2 (ja) * | 2010-12-01 | 2017-08-30 | アルダーバイオ ホールディングス エルエルシー | 抗ｎｇｆ組成物およびその使用 |
| UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| EP2930188A1 (en) | 2014-04-13 | 2015-10-14 | Affimed Therapeutics AG | Trifunctional antigen-binding molecule |
| US10519248B2 (en) * | 2014-07-25 | 2019-12-31 | Memorial Sloan Kettering Cancer Center | Bispecific HER2 and CD3 binding molecules |
| WO2016019969A1 (en) * | 2014-08-08 | 2016-02-11 | Ludwig-Maximilians-Universität München | Subcutaneously administered bispecific antibodies for use in the treatment of cancer |
| EP2990416B1 (en) * | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
| WO2016115274A1 (en) * | 2015-01-14 | 2016-07-21 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| EP3288975A1 (en) * | 2015-04-29 | 2018-03-07 | Institute for Research in Biomedicine | Ultra-potent neutralization of cytokines by multispecific antibodies and uses thereof |
| WO2017011342A1 (en) * | 2015-07-10 | 2017-01-19 | Abbvie Inc. | Igm-or-ige-modified binding proteins and uses thereof |
| EP3156417A1 (en) * | 2015-10-13 | 2017-04-19 | Affimed GmbH | Multivalent fv antibodies |
| KR20180096789A (ko) * | 2016-01-11 | 2018-08-29 | 인히브릭스, 인크. | 다가 및 다중특이적 41bb-결합 융합 단백질 |
| IL262241B2 (en) * | 2016-04-13 | 2024-05-01 | Sanofi Sa | Trispecific and/or trivalent binding proteins with a crossover dual variable domain arm and a traditional antibody fab arm, pharmaceutical composition comprising said binding proteins and their uses in preventing and/or treating cancer or inflammatory diseases |
| JP7038353B2 (ja) * | 2016-04-13 | 2022-03-18 | ヴィヴィア バイオテック，エス．エル | エクスビボのｂｉｔｅ活性化ｔ細胞 |
| US10188749B2 (en) * | 2016-04-14 | 2019-01-29 | Fred Hutchinson Cancer Research Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
| IL262365B2 (en) | 2016-04-15 | 2024-11-01 | Alpine Immune Sciences Inc | Immunomodulatory proteins ICOS ligand variants and uses thereof |
| WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| CN106589129B (zh) | 2016-12-30 | 2021-03-05 | 上海近岸生物科技有限公司 | 一种结合cd19、cd3和cd28的三功能分子及其应用 |
| TWI828625B (zh) * | 2017-06-25 | 2024-01-11 | 美商西雅圖免疫公司 | 引導及導航控制蛋白質以及彼之製造及使用方法 |
| SG11201912865VA (en) * | 2017-06-25 | 2020-01-30 | Systimmune Inc | Multi-specific antibodies and methods of making and using thereof |
| CN116948035A (zh) * | 2017-06-25 | 2023-10-27 | 西雅图免疫公司 | 多特异性抗体及其制备和使用方法 |
| US20210008113A1 (en) * | 2018-03-27 | 2021-01-14 | Systimmune, Inc. | Methods of making and using guidance and navigation control proteins |
-
2019
- 2019-03-26 US US17/040,519 patent/US20210008113A1/en active Pending
- 2019-03-26 WO PCT/US2019/024111 patent/WO2019191125A1/en not_active Ceased
- 2019-03-26 CN CN201980006977.5A patent/CN111527108A/zh active Pending
- 2019-03-26 SG SG11202008470WA patent/SG11202008470WA/en unknown
- 2019-03-26 CN CN202410657080.1A patent/CN118580363A/zh active Pending
- 2019-03-26 IL IL271348A patent/IL271348B2/en unknown
- 2019-03-26 CN CN202311257564.9A patent/CN117285641A/zh active Pending
- 2019-03-26 AU AU2019243453A patent/AU2019243453B2/en active Active
- 2019-03-26 JP JP2020551503A patent/JP2021519289A/ja active Pending
- 2019-03-26 KR KR1020207019089A patent/KR20200139130A/ko active Pending
- 2019-03-26 EP EP19776947.4A patent/EP3774918A4/en active Pending
- 2019-03-26 CN CN201980006846.7A patent/CN111566127B/zh active Active
- 2019-03-26 IL IL312224A patent/IL312224B2/en unknown
- 2019-03-26 WO PCT/US2019/024105 patent/WO2019191120A1/en not_active Ceased
- 2019-03-26 US US17/040,513 patent/US12029761B2/en active Active
- 2019-03-26 SG SG11202008474QA patent/SG11202008474QA/en unknown
- 2019-03-26 CN CN202311257825.7A patent/CN117285642A/zh active Pending
- 2019-03-26 IL IL319102A patent/IL319102A/en unknown
- 2019-03-26 JP JP2020551549A patent/JP7573441B2/ja active Active
- 2019-03-26 CA CA3094997A patent/CA3094997A1/en active Pending
- 2019-03-26 EP EP19775882.4A patent/EP3773621A4/en active Pending
- 2019-03-26 CA CA3094996A patent/CA3094996A1/en active Pending
- 2019-03-26 AU AU2019243448A patent/AU2019243448B2/en active Active
- 2019-03-26 KR KR1020207019088A patent/KR20200135935A/ko active Pending
- 2019-03-26 IL IL271325A patent/IL271325B2/en unknown
- 2019-03-27 TW TW108110660A patent/TW202003037A/zh unknown
- 2019-03-27 TW TW108110699A patent/TW201945013A/zh unknown
-
2023
- 2023-12-22 JP JP2023216572A patent/JP2024045111A/ja active Pending
-
2024
- 2024-08-02 AU AU2024205487A patent/AU2024205487A1/en active Pending
- 2024-08-02 AU AU2024205484A patent/AU2024205484A1/en active Pending
- 2024-10-15 JP JP2024180215A patent/JP7781243B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021519289A5 (https=) | ||
| Kiesgen et al. | Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity | |
| Liu et al. | mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion | |
| Liu et al. | Targeting epidermal growth factor‐overexpressing triple‐negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor | |
| Jin et al. | CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers | |
| JPWO2019191125A5 (https=) | ||
| Mottok et al. | Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies | |
| Leong et al. | B cells in lung cancer—not just a bystander cell: a literature review | |
| Wang et al. | Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and solid tumor microenvironment | |
| Rotiroti et al. | Targeting CD33 in chemoresistant AML patient-derived xenografts by CAR-CIK cells modified with an improved SB transposon system | |
| Chen et al. | CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy | |
| Afolabi et al. | Exploiting the CRISPR‐Cas9 gene‐editing system for human cancers and immunotherapy | |
| WO2020057486A1 (zh) | 经修饰的t细胞、其制备方法及用途 | |
| Seifert et al. | Impact of the selective A2AR and A2BR dual antagonist AB928/etrumadenant on CAR T cell function | |
| Shiozawa et al. | Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells | |
| Ouyang et al. | FGFR3 alterations in bladder cancer stimulate serine synthesis to induce immune-inert macrophages that suppress T-cell recruitment and activation | |
| JP2021502330A (ja) | Ｔｉｇｉｔおよび／またはｃｄ１１２ｒを標的とするか、またはｃｄ２２６過剰発現を含む、組成物および免疫治療の方法 | |
| Bisig et al. | New biomarkers in T-cell lymphomas | |
| Chaudhary et al. | Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer | |
| Sim et al. | Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development | |
| Ramesh et al. | Chimeric antigen receptor T‐cells: Properties, production, and quality control | |
| Zhu et al. | Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer | |
| Cao et al. | CXCR4 orchestrates the TOX-programmed exhausted phenotype of CD8+ T cells via JAK2/STAT3 pathway | |
| Moreno-Lama et al. | Coordinated signals from PARP-1 and PARP-2 are required to establish a proper T cell immune response to breast tumors in mice | |
| Zhu et al. | CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside |